Nicole Verdun
CBER Super Office Director, Office of Therapeutic Products (OTP), FDA
Dr. Verdun (ver-done) received her undergraduate degree from Duke University and her medical degree from the University of Chicago Pritzker School of Medicine. She then completed a Pediatrics Residency at Children’s Memorial Hospital-Northwestern University and a Pediatric Hematology-Oncology Fellowship at the Children’s Hospital of Philadelphia (CHOP). After practicing as a hematologist with a focus on hemostasis and thrombosis, Dr. Verdun joined FDA in 2012, first in the Office of Hematology Oncology Products as a medical officer and a liaison for sickle cell therapeutics and anticoagulants, and then Therapeutic Biosimilars. She was appointed as the Deputy Director of the Office of Blood Research and Review in the Center for Biologics Evaluation and Research (CBER) in October 2016 and was promoted to Office Director in 2018. In 2023, Dr. Verdun was selected as the Super Office Director of the Office of Therapeutic Products, overseeing 6 Offices dedicated to the regulation and approval of Cell and Gene therapies in the United States. She overseas both a research and regulatory portfolio in CBER.